Projects per year
Abstract
Malarial parasites employ actin dynamics for motility, and any disruption to these dynamics renders the parasites unable to effectively establish infection. Therefore, actin presents a potential target for malarial drug discovery, and naturally occurring actin inhibitors such as latrunculins are a promising starting point. However, the limited availability of the natural product and the laborious route for synthesis of latrunculins have hindered their potential development as drug candidates. In this regard, we recently described novel truncated latrunculins, with superior actin binding potency and selectivity towards P. falciparum actin than the canonical latrunculin B. In this paper, we further explore the truncated latrunculin core to summarize the SAR for inhibition of malaria motility. This study helps further understand the binding pattern of these analogues in order to develop them as drug candidates for malaria.
| Original language | English |
|---|---|
| Pages (from-to) | 679-693 |
| Number of pages | 15 |
| Journal | ChemMedChem |
| Volume | 16 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 17 Feb 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Actin inhibitors
- heterocycles
- latrunculin analogues
- malaria
- natural products
- P. falciparum
Projects
- 2 Finished
-
Small molecule therapeutics: from infectious and parasitic diseases to cancers
Baell, J. (Primary Chief Investigator (PCI))
1/01/17 → 31/12/21
Project: Research
-
NHMRC Research Fellowship
Baell, J. (Primary Chief Investigator (PCI))
NHMRC - National Health and Medical Research Council (Australia)
1/01/12 → 31/12/16
Project: Research
Equipment
-
Australian Translational Medicinal Chemistry Facility (ATMCF)
Stupple, P. (Manager)
Faculty of Pharmacy and Pharmaceutical SciencesFacility/equipment: Facility
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver